Eclipse 2000 To Compete Against PLC's Heart Laser In TMR Market
This article was originally published in The Gray Sheet
Executive SummaryPLC Medical's Heart Laser 1% perioperative mortality in stable angina patients may be viewed by cardiac surgeons as a significant advantage over the 5% rate for the Eclipse 2000, which was recommended for approval by FDA's Circulatory System Devices Panel at its Oct. 27 meeting. Both lasers are used in transmyocardial revascularization procedures to treat angina.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.